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Abstract 
An estimated 17% of all new cancers in women worldwide are due to cancers of the cervix, 
the ovary and the uterus. Together these cancers account for 14.6% of all female cancer 
deaths. This is a significant societal and economic burden which can be limited through 
cancer screening.  In the developed world marked reductions of 50%-90% in disease rates 
have been observed as a result of cervical cancer screening. In contrast in developing 
countries, where more than 85% of all new cases and deaths from this cancer are reported, 
significant challenges need to be overcome.. Although cytology remains a key component of 
cervical screening, the newer molecular tests offer a more targeted, risk-attuned approach. 
The situation for the other two gynaecological cancers is different.  The case for ovarian 
cancer screening has yet to be made, with the results of key screening trials in high- and 
low-risk populations still pending.  Screening for endometrial cancer is traditionally not 
advocated as women become symptomatic during the earlier, treatable stages of disease.  
However, consideration of screening options for these two cancers is warranted since 
endometrial cancer rates are on the increase with women and in ovarian cancer the high 
case fatality ratio remains unchanged.  
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Main article  
Introduction 
The most commonly occurring gynaecological cancers are those affecting the cervix, the 
ovary and the womb. Figures released by Globocan [201] show that these cancers 
accounted for an estimated 17% of all new cancer cases in women worldwide and 14.6% of 
all female cancer deaths in 2008. As the world population expands, ages, and increasingly 
adopts lifestyles which may be detrimental to health, the global rates of cancer are expected 
to rise [1]. For gynaecological cancers this could mean an estimated increase in incidence 
and mortality rates of 66% and 62% respectively by 2030, based on anticipated population 
growth and current trends [201]. There is significant need to invest in and refine measures to 
limit this potential growth, especially in low – middle income countries (LMIC) where cancer 
impact is expected to be the greatest and where resources are limited and societal norms 
may in addition, engender inequalities in women’s healthcare.  One strategy for managing 
the disease burden is through screening asymptomatic individuals for the presence of 
early/preinvasive disease. This approach has already produced considerable success in 
reducing cervical cancer rates by 50-90% in the industrialised countries [2]. However, 
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cervical cancer still remains a key public healthcare concern in the LMIC countries. In this 
article we review the current burden of the common gynaecological cancers, the unique 
challenges each of these conditions pose and the approaches that are used for screening 
and early detection of disease. 
 
Cervical cancer 
Cervical cancer is the third most commonly diagnosed cancer and the fourth leading cause 
of death in women worldwide [201,1]. An estimated 275,000 deaths and 529,800 new cases 
were attributed to this disease in 2008, with the majority of new cases (453,300)and deaths 
(242,000) being observed in the developing nations. The highest incidences were in Africa 
(Eastern (age–standardised rate (ASR) 34.5), Western (33.7) and Southern regions (26.8), 
South-Central Asia (24.6) and South America (23.9) per 100,000. The lowest incidences 
were reported in North America, New Zealand/Australia, with ASRs of 5.7 and 5.0 per 
100,000 respectively. For mortality, the ASRs per 100,000 were 25.3 and 24.0 for Eastern 
and Western Africa respectively compared to 2.0 for Western Europe, 1.7 for North America 
and 1.4 for Australia/New Zealand per 100,000.  
The differences in cancer rates between the industrialised nations and the developing world 
reflect the lack of well organised screening programmes in the latter nations. [3]. Poverty, 
lack of education and access to medical care are all contributory factors to high level of 
cervical cancer cases and deaths in the developing countries. The cancer is often diagnosed 
at a late stage and the infrastructure may not exist to provide timely or appropriate treatment.  
In developed countries disparities may be observed in women from the medically 
underserved communities [4].  Approximately 50% of all cervical cancer cases in the US are 
in women who have never been adequately screened [5]. 
Cervical cancer, which meets most of the WHO criteria for screening (Table 1) [6] is the only 
gynaecological cancer for which mass screening programmes exist.  These are either 
centrally managed and based on computerised call /recall systems as in the United Kingdom 
[UK] and some European countries or are opportunistic as in the USA and Canada.  The key 
to success is adequate coverage, high quality screening programmes, and access to 
treatment. 
 
Cervical cancer typically develops over 2-3 decades with changes beginning in the 
transformation zone of the cervix. Histologically, the pre-cancerous changes are termed 
cervical intraepithelial neoplasia (CIN). In CIN1, which is classed as a low grade lesion, 
nuclear atypia is seen in the lower third of the epithelium. There may be polyploidy and bi or 
multinucleated cells, mitotic figures and a variety of cytopathic effects indicative of a viral 
infection and are especially prominent in CIN1[7]. 
CIN2 and CIN3 are classed as high grade lesions. In these lesions, atypia is present in all 
layers of the squamous epithelium to an extent and degree far exceeding CIN1. Other 
features include increased nuclear cytoplasmic ratio and hyperchromatic nuclei. Immature 
basal-type cells typically occupy more than the lower third of the epithelium. In CIN2, the 
lower two thirds of the epithelium are occupied by neoplastic basaloid cells. In CIN3 there is 
further expansion of cellular changes with immature basaloid cells occupying the upper third 
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of the cervical epithelium. CIN3 is also referred to by some as stage 0 carcinoma / 
carcinoma in situ. Both high and low grade CIN lesions can co-exist and not all CIN, 
including CIN3 progress to invasive carcinoma. 
 
The large majority of lesions, especially CIN1, regress spontaneously or remain stable. 
Recent re-evaluation of data derived from an unethical study conducted in New Zealand 
during the 1960s and 70s, where treatment was withheld or delayed in CIN3+ women, 
showed that 30-50% of CIN3 will progress to malignancy over a 30 year period [8].    
The confirmation in the 1980s that the causative agent for cervical cancer was Human 
Papilloma Virus (HPV) was a landmark event which changed the landscape for primary and 
secondary prevention of this disease [9,10]. HPVs are small, unenveloped DNA viruses that 
are common in both men and women and are transmitted mainly through sexual contact or 
skin-to skin contact. HPVs exhibit species and tissue trophism and of the 120 genotypes 
identified from human tissue, over 40 genotypes have the ability to infect the human genital 
tract [11, 12]. Fifteen of these have been identified as high risk for cervical cancer [13] and 
twelve [HPVs 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59] are already classed as 
carcinogens by WHO [14]. A recent cross sectional study involving 38 countries 
demonstrated that HPV16 and HPV18 [15] are the most prevalent of all genotypes in all 
regions and responsible for 71% of all cervical cancer cases. HPV16, HPV18 and HPV45 
jointly were responsible for 94% of adenocarcinomas.  
Infection rates are high soon after onset of sexual activity and women can be simultaneously 
infected with multiple types at any one time. Infection by itself does not lead to cancer and in 
many cases is cleared within 1-2 years [12] and the women may not even be aware that they 
are infected as there are no symptoms. A key risk factor for cancer development is 
persistence of infection with oncogenic types. It is still not fully understood what allows viral 
persistence but the prominence of HPV16 may be related to its ability to persist for a longer 
period than other types [12]. Two oncoproteins closely associated with the tumoriogenic 
process are E6 and E7. These are significant in disrupting the normal functioning of tumour 
suppressors p53 and pRb, causing loss of cell cycle control and producing genetic instability 
[16, 17]. Overexpression of these oncoproteins is associated with an increased risk of 
disease progression. The oncoprotein E5 augments their function and supports tumour 
progression [17]  
Risk cofactors for development of cervical cancer are smoking, long term use of 
contraceptives, multiparity, multiple partners early age of sexual activity, and co-infection 
with other STD related microorganisms [eg Chlamdyia] [202] (Ref 202). Individuals who are 
immunocompromised, for example in HIV or organ transplant recipients, are at 2-3 times 
greater risk for cervical cancer and may need to be screened more frequently.  
Cervical cytology 
Exfoliative cytology remains the primary means of testing in many countries [202, 18] though 
recent developments allow for molecular testing as part of a co-testing strategy or for triage 
of abnormal findings.  The mainstay for screening for decades has been the Papanicoloau 
test which was first described in the 1940s [19]. Though widely used and exhibiting high 
specificity, the test is not very sensitive, with these being estimated at the threshold of 
atypical cells of undetermined significance [ASCUS] at 98% (95% CI 97%-99%) and 51% 
(95% CI 37%-66%) respectively [20]. In a meta-analysis of 62 studies, specificity of 
4 
 
conventional cytology ranged between 14%-97% and sensitivity between 11-99% [21].The 
assay is prone to sampling errors and air drying artefacts. The reading of the slides and 
interpretation of the results is subjective with detection errors.  These shortcomings are 
thought to underlie the lower sensitivities (high false negative rates) reported with this assay 
in many countries [22, 23].  
In an attempt to resolve these problems liquid based cytology (LBC) was introduced in the 
mid-1990s-2000s [24,25]. It involves samples being collected from the transformation zone 
of the cervix using a special brush and placed into a fixative liquid. An automated process 
prepares a thin layer of cells on a slide which is then stained for analysis. The use of 
ThinPrep was approved by the FDA in 1996 [25]. Other commercially available LBC systems 
include SurePath, Cytoscreen and Labonard Easy Prep. Reading of the slides can also be 
automated using the ThinPrep Imaging System (Hologic, Bedford, MA, USA) or the 
FocalPoint GS Imaging System (BD Diagnostics,Franklin Lakes, NJ, USA). The recent 
MAVARIC trial however, reports that automation-assisted reading is 8% less sensitive than 
manual reading [26]. 
 
In the UK LBC was recommended as the primary test in the NHS cervical screening 
programme in England and Wales by the National Institute for Clinical Excellence (NICE) in 
2003 [27].  The changeover to this technology was completed in 2008 [202]. Compared to 
Pap-smears, LBC is associated with fewer inadequate/ unsatisfactory smears and in initial 
studies had higher sensitivity for abnormal smears However, a recent meta-analysis which 
used gold standard verification, based on colposcopy and histology of colposcopy-targeted 
biopsies, found no significant difference in sensitivity and specificity for histologically 
confirmed CIN 2 or worse between LBC and traditional pap-smears [28].  
 
Various systems exist for reporting cytology results (Table 2). The Bethseda System (TBS) 
first proposed in 1988 and subsequently revised in 1991 and 2001 is employed in the USA 
[29].  In the United Kingdom the British Society of Clinical Cytology (BSCC) terminology for 
reporting cervical cytology results was first described in 1986 [30]  with  recommendations 
for amendments being  made recently [31,32]. In the original system dyskaryotic cells were 
classified as mild, moderate, or severe according to the nuclear and cytoplasmic ratios and 
the degree of morphological abnormalities. The new proposed changes to the terminology in 
the UK are more closely aligned with TBS. Any abnormal result is followed by colposcopy 
and biopsy as per local guidelines and diagnosis is made on histological analysis.    
Visual Inspection tests 
Screening with cytology based assays requires a well organised, resource intense 
infrastructure which is expensive to run. In addition, it relies on women being able to return 
to the clinic for repeat testing or treatment.  As a result other methodologies have been 
developed for use in low-resource settings [33,34]. These are mainly tests that rely on visual 
inspection of the cervix. This can be performed after application of 3-5% acetic acid (VIA), 
visual inspection with a magnifying glass (VIAM), visual inspection after Lugol’s iodine (VILI). 
VIA is the most frequently used option and involves application of dilute acetic acid to the 
cervix with a cotton swab or a spray followed a minute later by scanning the transformation 
zone with the aid of a bright light for areas of acetowhitening. The results are classed as 
positive or negative depending on extent of the acetowhitening using defined criteria [34]. 
However, interpretation of results may be difficult where the area of transformation zone is 
5 
 
poorly visible or in postmenopausal women because of degenerative changes in the cervical 
epithelium. The advantages of this test are that it is fast, cheap and results are immediately 
available and the screening personnel can be trained within a matter of weeks. However, the 
test is subjective and results are variable and not always reproducible if quality assurance 
procedures are not standardised.  The reported sensitivity and specificity ranges are wide, 
31–95% and 49–97% respectively, with PPV of 5–20% and NPV 92–99% [34]. 
Comparisons of studies have been hampered because of the use of different disease 
thresholds and variable access to confirmatory diagnosis. A recent comprehensive meta-
analysis [35] identified 77 cross sectional studies using VIA. In 26 of these studies where the 
results were confirmed histologically in all screened women, the technique had a sensitivity 
of 80%, specificity of 92% with a PPV of 10% and NPV 99%. In other investigations where 
VIA has been compared with cytology the sensitivity of VIA has been reported to be 
equivalent or higher but the specificity lower than cytology In a cluster, randomized, 
controlled trial in India a single round of VIA, followed by immediate colposcopy and 
treatment produced a significant reduction (35%) in mortality at 7 years [36]  
 
HPV testing  
The observation that virtually all cervical cancer cases (99.7%) are due to HPV focused 
attention on the detection of viral DNA [37]. Several assays for HPV have been developed. 
Mostly these are DNA hybridisation or PCR based assays. One of the earliest second 
generation tests approved by the FDA was the Hybrid Capture 2 (HC2) assay Qiagen, 
Gaithersburg, MD, USA) in 2003. This test detects 13 high risk (HR) HPV types and has 
been used as a comparator for the development of a number of the newer assays, which 
measure presence of 14 HR-HPV types and/or also separately determine levels of HPV16 
and 18 expression. These tests include FDA approved Cervista HPV HR test and Cervista 
HPV 16/18 (Hologic Inc, Madison, WI, USA),  Roche’s Cobas 4800 HPVtest (Roche 
Molecular Systems, Inc. Pleasanton, CA) and Abbots RealTime test (Abbots Molecular Inc. 
Des Plaines, IL, USA). In addition, in 2011, assays such as the Aptima test (Gen-Probe Inc, 
San Deigo, CA) to measure presence of viral oncoproteins E6 and E7 mRNA levels were 
approved.  
 
Numerous trials and studies have shown that compared to cytology, HPV testing is more 
reproducible, stable over a range of ages, has higher negative predicative value and better 
sensitivity but specificity is lower [38-41]. When used in combination with cytology, higher 
sensitivities are observed [42]. Recent trials have compared HPV testing plus cytology 
versus cytology alone [43, 44]. Results show that fewer high grade lesions were detected at 
the second round of screening than when cytology alone was used. In addition, a 
significantly lower number of cervical cancers or none were detected at the second round in 
the intervention groups of the POBOSCAM [44] and NTCC [45] trials respectively 
HPV testing has been incorporated into the screening strategies in a number of countries, 
including the UK [6, 46,47,203-]. In particular, the technique has been used as a ‘reflex ‘test 
for triaging women who have equivocal smears or for checking samples for proof of cure 
(Table 3). In England, the pilot studies investigating HPV triage reported an increase in the 
number of women who were referred to colposcopy with a decrease in the number requiring 
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repeat cytology and in the time it took to return women to routine screening. [48-50]. An 
economic analysis indicated that though HPV triage was expensive it was more cost 
effective in terms of quality and lives saved [48,,49].  
 
In the US, HPV testing was introduced earlier in the 2000s [25,51], being used in triage of 
equivocal cytology only in women 30yrs and older. In younger women, transient infections 
may be detected by the assay, leading to undue anxiety and unnecessary excision 
procedures that are known to increase risk for preterm deliveries. In older women the 
presence of HPV is likely to indicate persistent infection. The U.S. Preventive Services Task 
Force [USPSTF] [46] and the ACP/ASCCP/ ASCP,  American College of Pathologists/ 
American Society for Colposcopy and Cervical Pathology/ America Society for Clinical 
Pathology; guidelines for cervical screening [6] were updated earlier this year. There is good 
concordance for the recommendations between the two groups with both guidelines 
supporting longer intervals [3/5yrs] between routine testing. The main difference is that the 
former guidelines still recommend cytology as the primary test with use of HPV testing for 
triage and test of cure and for those requesting extension of the 3-year screen interval to 5-
years. The ACP/ASCCP/ ASCP recommend co-testing.  
 
HPV testing has an additional benefit in being able to help identify women who have 
adenocarcinomas, which form 15% of all cervical cancers [ ref 204]. In countries where 
screening programmes exist an increase in adenocarcinomas has been noted [52]. Further 
refinements have come in the shape of assays that separately measure the HPV16 and 18 
genotypes. Data from the recent ATHENA trial shows that assessment of HPV16 or 18 
separately can lead to better separation of women who, following an ASC-US or NILM result, 
are at the greatest risk of developing high grade lesions [53-55]. ASC-US positive women, 
who were HPV16+HPV18+ had nearly twice the absolute risk of CIN2+ or worse  compared 
to women who tested positive for all high risk HPV genotypes combined (24.4% vs 14.%). In 
addition, women who had negative cytology but HR-HPV positive, the data revealed that 
HPV16+,HPV18+ women had 11.4% absolute risk of CIN2 or worse compared to the 6.1% 
of women who tested positive for all HR-HPV genotypes. 
Along similar lines to further stratify women who were at the highest risk of developing 
cancer, the first tests to measure E6/E7 mRNA are now available. Presence of HPV does 
not mean that malignant transformation will occur, whereas E6 and E7 expression, which is 
closely linked with this process is a stronger indicator of malignancy. A recent systematic 
review which included eight studies using the APTIMA test to triage women with a cytology 
result of ASC-US or LSIL showed that APTIMA is as sensitive as HC2 (54.9 vs 44.9) but has 
greater specificity (38.7 vs 27.8) for detecting CIN3+.[56]. The PreTECT HPV-Poofer E6/7 
mRNA test (Proofer; Norchip) was been reported to have higher specificity than APTIMA 
(75.1% vs 45.8%) but has lower sensitivity (79.1%vs 94.9%)  [57].Other methodologies 
investigating p16INKa expression or methylation status of a selection of tumour suppressor 
genes proliferation markers CDC6 and MCM5 are also being tested [58,59].The jury is out 
as to which of these tests may be the preferred method for further fine tuning HPV testing. 
There is now considerable interest in using HPV testing as the primary screening test for 
cervical cancer as it is objective, can be automated and has a high negative predicative 
value. Results from the extended follow-up of the ARTISTIC trial, suggest that the screening 
interval can be extended up to 6 years if HPV were the primary screening test as the 
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negative HPV test was significantly more protective than normal cytology over three 
screening rounds [60]. Data emerging from recent trials in low resource settings using HPV 
as the primary screen have also been very promising. In a cluster-randomised controlled trial 
in rural India [61] of 131,746 healthy women (aged 30-59yrs) randomised to receive a single 
one-time screen by HPV testing or VIA or cytology or standard care (no screening), 
significant reductions in advanced cancers (2.5 per 1000 to 1 per 1000) and deaths (50% 
mortality reduction at 7 years) were only observed in the HPV tested group compared to 
controls. In a separate trial marked reduction in CIN2-3 lesions were observed 36months 
after treatment in women who had previously been tested using HPV compared to VIA. [62].  
 
The existing HPV technology is expensive in a low resource setting. An alternative lower 
cost rapid throughput test, CareHPV has recently been tested in a rural setting in China. The 
assay had demonstrated higher sensitivity [90%] for identifying moderate or severe cervical 
disease [CIN 2+] compared either VIA (41%) or LBC (85%). The test requires no electricity 
or running water and results are available in 2.5hrs. [63]. Demonstration projects of 
CareHPV screening are now underway in other low-income countries (India, Uganda and 
Nicauragua).  
 
All HPV tests lend themselves to self-sampling which may help overcome societal barriers to 
gynaecological testing. Self-sampling may be a means to reach women who have been 
previously unscreened [64]. A recent meta-analysis examining results of self-sampling tests 
versus those collected by clinical staff reported concordance between the two collection 
methods showing that self-collection of samples was acceptable for HPV DNA detection 
[65]. Self-sampling has also been tested investigated in studies in China [66] and sensitivity 
and specificity was in moderate agreement with those obtained with physician based 
collections. 
 
In light of recent data that is currently emerging with HPV as the primary test, piloting of HPV 
testing with reflex cytology in the UK has recently been announced [67]. Careful 
consideration of the age at which this begins is required to avoid overdiagnosis and 
treatment in younger women who may have high levels of transient infections. Data from the 
POBOSCAM trial suggests testing could begin at 29years of age whereas data from the 
NTCC trail suggests that HPV testing should start at a later age [44,45]. 
 
Impact of vaccination on cervical screening 
In 2009 WHO recommended that HPV vaccines be used for prevention of cervical cancer 
[68]. There are two HPV vaccines against HPV 16 and 18 are Gardasil [Merck, USA] and 
Cervarix [GSK, UK], which are highly efficacious in preventing high grade abnormalities [69]. 
Very high levels of anti-HPV16 and 18 antibodies are generated, which modelling studies 
predict can provide protection up to 20yrs The vaccination programmes have been taken up 
more than 100 countries and has targeted adolescent girls, mainly aged 12-17yrs of age. 
Already reduction in CIN3+ incidence in young women <18yrs have been noted. A reduction 
in the burden of cervical cancer especially in the developing countries and also in lower 
socioeconomic groups is anticipated and some reductions have already been reported [69]. 
However, women who have not had vaccination should continue to be screened and 
screening continues to be recommended in case the vaccines do not provide adequate 
cover against other HPV types.  
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Current recommendations on cervical cancer screening in low resource settings 
Modelling using data from field studies suggest that in low resource settings, if a woman is 
screened for cervical cancer only once in her lifetime between the ages of 30 and 40, her 
risk of cancer would be reduced by 25-36%. If the women were screened twice (at ages 35 
and 40) in their lifetime for cancer the modelling predicted their cancer risk would be reduced 
by 76% with HPV DNA testing and if VIA was used, by 65%. The cost per life year saved 
using such a strategy would be less than each country’s per capita gross domestic product. 
This strategy would be highly cost effective by the standards established by the WHO’s 
Commission on Macroeconomics and Health [70]. The most recent guidance from the WHO 
recommends that all countries should have a documented cervical cancer prevention 
strategy that includes public education built on existing outreach programs and should define 
a centre or centres of excellence for the management of cervical cancer [71]. Bangladesh is 
one of the first among the low income countries to implement a national VIA screening 
programme [72]. 
 
Ovarian Cancer  
Ovarian cancer [OC] continues to be the most lethal of gynaecological cancers. More than 
sixty percent of women diagnosed with this condition will be dead within five years of initial 
diagnosis in spite of cytoreductive surgery and improved therapeutic regimens. In the UK 
according to 2008 figures, this translates to 4,373 lives lost. In the same year 6,500 new 
cases will have been diagnosed [ ref 205]. Globally, ovarian cancer accounts for 3.7% of all 
female cancers worldwide, with an estimated 225,000 new cases diagnosed  and 140,000 
deaths occurring in 2008 [201 ]. Women in the industrialised nations are almost twice as 
likely develop ovarian cancer [ASR 9.4 per 100,000] compared to the developing nations 
[ASR 5.0 per 100,000] [1].  The highest ovarian cancer incidence rates are recorded in 
Europe and the Northern America, and the lowest rates in Africa and parts of Asia. 
 
Although there have been recent attempts to raise awareness of the symptoms of the 
disease [206,207], available mortality rates indicate that women are continuing to be 
diagnosed with advanced disease which has spread beyond the ovary. When the cancer is 
diagnosed at an early stage (Stage I), prognosis is much better; and more than 90 % of 
women are reported to survive for 5 years or more [208].  
 
At present there are no national screening programmes for ovarian cancer akin to those in 
cervical cancer. Large trials have been instigated to investigate the strategies best suited to 
detect preclinical disease in women who are most at risk. These fall into two groups: (1) 
General population - Women >50 years with no significant family history [this includes none 
or one relative with ovarian cancer] (2) High-risk population - Women >35 belonging to 
familial breast and/or ovarian cancer families. First-degree female relatives of cancer 
sufferers in such families have a lifetime risk of developing ovarian cancer of approximately 
>10%. [73] Germline mutations in the genes, BRCA1 and BRCA2, account for a high 
proportion of this risk. Mutations in BRCA1 are associated with a lifetime risk of ovarian 
cancer of about 40-50% and mutations in BRCA2 with 11-26%. The OC risk for women with 
Lynch syndrome is approximately 10% [73].  
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Screening methodologies 
The techniques which have been used alone, sequentially or in combination to screen for 
OC have been adopted from routine clinical practice. These include pelvic examination, 
ultrasonography and assessment of serum CA125 levels. Because of the low prevalence of 
ovarian cancer in the population the challenge has been to achieve sufficient specificity 
(>99.6% for 10% PPV) [74] to avoid high false positives rates as cancer diagnosis can only 
be confirmed following surgery and histological examination of the removed adnexa. Pelvic 
examination has not the sensitivity nor specificity required by early detection of ovarian 
cancer and has largely been discarded for this purpose. 
Ultrasound  
The availability of real-time ultrasonography for gynaecological examinations led to the 
suggestion that ultrasound examination of ovarian size and morphology could be used to 
screen for ovarian cancer [75, 76]. It has been used both as a primary and second line 
screening test. Transvaginal ultrasound (TVS) is the preferred method for visualising ovaries 
compared to the transabdominal approach because of better resolution. TVS is both 
acceptable to the women and has low inter-observer variation [77, 78]. Because of the 
subjective nature of the technique, a key concern has been to provide a framework for 
distinguishing benign adnexal masses from those that are malignant to avoid the need for 
excessive surgery. Published data show that some features of the ovarian morphology 
(papillary projections, complex ovarian cysts with wall abnormalities or solid areas] are 
strongly associated with the presence of malignancy compared to others (septal thickness, 
unilocular ovarian cysts <10cm in diameter and inclusions cysts) and are the basis of various 
algorithms used for differential diagnosis of a pelvic mass [79, 80]. In the absence of data on 
ultrasound appearance of preclinical lesions, most ovarian cancer screening trials have 
defined all ovarian cysts with complex morphology as abnormal and used repeat scans and 
clinical evaluation to manage abnormal findings. The major trial that has reported 
prospective use of a morphology score is the University of Kentucky Ovarian Cancer 
Screening Trial [81]. In the course of the trial 55% of all the abnormalities detected by 
screening were ovarian cysts less than 10 cm in diameter or septated cysts without solid 
areas or papillary projections and none progressed to malignancy. The original tumour 
profiling index was modified to return these women to annual screening. As a result of these 
modifications the positive predictive value (PPV) of ultrasound in this trial rose from 14.1% to 
20.2% [81]. 
Postmenopausal ovaries can be difficult to visualise, especially with diminution of these 
organs with age. In UKCTOCS, quality assurance programmes were established for 
ultrasound scanning in an attempt to ensure that scanning quality was as uniform as 
possible across all sites. All ultrasonographers were required to undertake an initial program 
of training for screening postmenopausal ovaries and followed by a process of examination 
for accreditation which then had to be renewed bi-yearly. The impact of introducing the 
accreditation programme into UKCTOCS is currently under analysis. 
CA125 
CA125 [MUC16] is a high molecular weight [average 2.5-5 MDa], Type 1 transmembrane 
glycoprotein, which is overexpressed in ovarian cancer [82]. It was first described by Bast et 
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al in 1981 through its binding with murine monoclonal antibody OC125 [83]. CA125 
comprises a heavily glycosylated extracellular domain, an intra-membranous domain and a 
short cytoplasmic tail [82]. Shedding of the extracellular domain is thought to occur in 
response to intracellular signalling. The normal function of CA125 is not known but the first 
direct evidence for a functional role in ovarian cancer cells has recently been presented [82]. 
The mucin modulates tumor cell growth, cell motility, invasive and metastatic properties and 
tumorigenesis. Tumour growth may also be influenced through the inhibition of natural killer 
cells [84]. CA125 is not unique to ovarian cancer, with increased levels being observed in 
non-gynaecological malignancies, infections, inflammatory disease as well as being found in 
benign conditions such as menstruation, pregnancy and endometriosis [73]. 
 
Serum CA125 is assessed through an immunoassay. The first of these used the OC125 
antibody for both capture and detection. This assay has been superceded by the widely 
used second generation heterologous CA125-II assays, that include a second monoclonal 
antibody M11 which recognises a different antigenic domain from OC125 [85]. A variety of 
assays are available, many of which are automated. However, differences in reagent 
specificities and assay design can lead to variation in values obtained, and means that the 
results may not be interchangeable and a changeover in assay requires parallel testing. 
 
A CA125 level of 35 IU/ml is usually accepted as the upper limit of normal. [86]. However, it 
has been suggested that cut-offs based on menopausal status maybe be more appropriate 
in screening asymptomatic women. A cut-off of 20 IU/mL has been suggested following 
menopause [87]. In a more recent analysis cut offs of approximately 50 IU/ml in 
premenopausal women, 40 IU/ml for premenopausal women on oral contraceptives and 35 
IU/ml for postmenopausal women have been suggested [88]. Approximately 85% of patients 
with epithelial ovarian cancer have CA125 levels of >35U/ml, with elevated levels found in 
50% of patients with Stage I disease and over 90% of patients with Stage II-IV disease [89]. 
Up to 20% of cancers, mainly mucinous and borderline do not express significant levels of 
CA125.  
 
The discovery that CA125 was raised 5 years in advance of ovarian cancer [90] led to it  
being investigated as a screening test. CA125 by itself does not perform well as a screening 
test. It has low sensitivity and specificity. However, when used in multimodal testing these 
parameters improve.  Sequential CA125 measurements and pelvic ultrasound in a trial of 
22,000 women, achieved a specificity of 99.9% and PPV of 26.8% for detecting ovarian and 
fallopian tube cancer [91] requiring four operations to detect one case of ovarian cancer. To 
improve performance, serial CA125 has been incorporated into algorithms to predict a 
women’s risk of ovarian cancer. In women with ovarian cancer CA125 levels tend to 
increase over time compared to other conditions such as benign gynecological disease 
where CA125 may be high but tend to remain constant [92]. Observing these patterns of 
change, Skates and colleagues developed a computerised Bayesian algorithm, Risk of 
Ovarian Cancer (ROC), using serum CA125 measurements [93]. Using an individual’s age-
specific incidence of ovarian cancer and her CA125 profile the algorithm generates a risk 
estimate (ROC value) based on comparing her pattern to those observed in women known 
to have been diagnosed with ovarian cancer.  The greater the correlation of the test pattern 
to established CA125 profiles in OC, the greater the ROC value and therefore the risk of OC 
[94]. Based on this estimation, women are triaged into low, intermediate and elevated-risk 
groups. The women at intermediate risk have a repeat CA125. Those that have an elevated 
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risk are referred for a repeat CA125 and transvaginal scanning. If either result is abnormal, 
the women are referred for clinical assessment with a gynaecological oncologist with a view 
to surgery. 
The ROC algorithm was first tested in a randomised controlled trial involving 13,582 
postmenopausal women. It showed a high specificity (99.8%; 95% CI 99.7 to 99.9) and PPV 
(19%; 95% CI 4.1 to 45.6) for primary invasive epithelial ovarian cancer [95]. It is currently 
being tested in trials in both high and low risk trials in the USA and UK [88,96, 97,209,].  
Combining CA125 with other biomarkers has been suggested as a means of improving 
sensitivity and specificity for detecting ovarian cancer early. A number of candidates, 
including prolactin, transthyretin or apolipoprotein A1, human epididymis protein 4 (HE4), 
CA72-4, and CA15-3, have been identified and tested [98,99]. However, none of 
combinations of markers have improved on CA125.  One biomarker however, which has 
shown promise is HE4, especially in early disease. This is elevated in epithelial ovarian 
cancers (EOCs) and not in benign gynaecological conditions and maybe helpful in cancers 
where CA125 is not expressed [100].  Its use as a second biomarker in a multimodal 
screening strategy is being investigated in the Novel Markers Trial. [210]. The Risk of 
Ovarian Malignancy Algorithm (ROMA), which uses HE4 alongside CA125 has recently 
been approved for differential diagnosis of patients presenting with adnexal mass and is not 
a screening test [ref 211]. 
 
Screening trials 
General population 
Initial evidence of improved survival with screening was provided by a randomised trial in 
21,935 women which showed higher median survival [72.9 months] in women with ovarian 
cancers detected in the screened arm compared to controls [41.8 months] who did not 
undergoing screening [101]. Subsequently, a number of large prospective screening trials 
have been conducted using CA125 alone, ultrasound alone or both in combination 
[81,97,102,103]. There are three randomised controlled trials and one population controlled 
trial. In the former group, the Shizuoka Cohort Study on Ovarian Cancer Screening 
[SCSOCS] trial [102] showed no significant difference in the number of cancers detected in 
the screened arm [n = 41,688] compared to control [n = 40,799] in low risk women using a 
combination of CA125 and TVS .  Although there were more early stage cancers in the 
screened arm [63%] compared to the control [38%], the difference was not significant.  The 
mortality rates from the Japanese trial are yet to be reported.  The Prostate, Lung, Colorectal 
and Ovarian [PLCO] Cancer Screening Trial [103], conducted in the US is the only large 
randomised trial to report mortality data, including both primary fallopian tube and peritoneal 
cancers. The trial recruited 78,216 postmenopausal women. Participants were screened 
using serum CA125, and transvaginal ultrasonography for 3 years, followed by CA125 alone 
for a further 2 years in those women who were still eligible. The women were followed up for 
a median of 12.4 years. Ovarian cancer was diagnosed in 212 women in the screened group 
and 176 in control women. Stage distribution was similar across the groups with most 
cancers being stage III/IV. Although the trial had adequate power, extensive outcome review 
and minimal contamination, no differences in ovarian cancer deaths or survival were 
observed in screened women compared to controls. In addition, 15% of women undergoing 
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surgery for benign pathology experienced at least one serious complication.  The  lack of 
effect may have been due to a number of reasons [104,105], and this includes the absence 
of a protocol driven management process, with the follow-up of abnormal results being left to 
the discretion of the women’s treating physician which may have resulted in delayed action. 
There was also no mention of a quality assurance programme to ensure delivery of high 
quality ultrasound. In addition, there was a dilution of screening effect, with 40.6% cancers in 
the study arm being diagnosed after screening ended [4-6 years screening and median 
follow up of 12.4 years], with those diagnosed more than 2 years after screening unlikely to 
have been affected by screening. The PLCO and the Japanese Cohort Study both used a 
single CA125 assessment with a 35IU/ml cut off. In an attempt to see if implementation of 
ROCA would have made a difference to the results of the ovarian arm of the PLCO, Pinsky 
et al [106] recently undertook modelling studies to test this using updated data from the 
PLCO trial. Although the model suggested that 43 cancers could have been detected earlier 
with ROCA, almost a median of a year in advance for fatal cases, a significant. mortality 
benefit would not have been observed.   
 
In United Kingdom Collaborative Trial of Ovarian Cancer Screening [UKCTOCS] [97] 
202,638 low risk women were randomised to one of three arms (ultrasound (U), multimodal 
(M), control (C)) in a ratio of 1:1:2. Women in the U arm underwent annual TVS and, those in 
the M group had a blood test for serum CA125 assay. The CA125 was interpreted using the 
ROC algorithm. Abnormalities were triaged according to well defined protocols to either 
repeat testing and/ or further investigations. In the prevalence screen 0·2% women from the 
MMS group and 1.8% from the U group underwent surgery. A total of 87 primary ovarian and 
tubal cancers, including 28 borderline tumours were detected. with 48·3% (95% CI 35·0–
61·8) of the invasive cancers stage I/II. There was no significant difference in the stage 
distribution between the groups. The sensitivity, specificity, and positive-predictive values for 
primary invasive epithelial ovarian and tubal cancers were 89·5%, 99·8%, and 35·1% for M 
group, and 75·0%, 98·2%, and 2·8% for U group respectively. Although the prevalence data 
look promising, any mortality benefit can only be assessed when results of the incidence 
screening are reported in 2015. UKCTOCS is still ongoing; screening in UKCTOCS 
completed in Dec 2011 and the women are currently in the follow-up phase. Results of this 
trial will inform the decision to have (or not) an ovarian cancer screening programme in the 
UK. Parallel studies to this trial are examining the health economics and also the 
psychosocial aspects of screening [107]. 
 
The University of Kentucky Ovarian Cancer Screening Trial [81], is a population controlled 
trial, which is a single arm trial using ultrasound as the primary screening tool, with 
morphology profiling. The screening algorithm used which has allowed for a higher 
specificity [98.8%] and PPV [20.2%] than thought possible for this technique [108]. The 
sensitivity for primary invasive epithelial was higher [79.7%] than that for ultrasound 
scanning in PLCO [67.4%]. In UKCTOCS prevalence screening sensitivity for ultrasound 
was 75%.  These authors reported that annual ultrasound screening of asymptomatic 
women resulted in increased detection of early ovarian cancer as well as a significant 
increase in the 5 year survival rate compared to women diagnosed clinically. Forty-seven 
invasive epithelial ovarian cancers and 15 epithelial ovarian tumours of low malignant 
potential were detected during 895,032 woman years of screening. 70% of the cancers 
detected were Stage I and II. Whilst data from the Kentucky trial offer hope, these findings 
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may reflect a combination of a healthy volunteer effect and lead time of screen detection. 
Reduction of mortality in a screened population in a randomised control trial is sorely needed 
for screening to have an impact on OC outcomes.  
 
High-risk women   
Annual screening in high risk women with a family history of ovarian/early breast cancer or 
mutations in genes such as BRCA1/2 is not regarded as efficacious [109]. Results from the 
recently reported Phase-1 of the UK Familial Ovarian Cancer Screening Study [UK FOCSS] 
indicated a sensitivity of 81.3-87.5%, PPV of 25.5% and NPV of 99.9% with annual 
screening. The findings indicated that screening more frequently than annually with prompt 
surgical interventionmay offer a better chance for detecting early stage disease [110]. 
Cancers in these women are often high grade serous EOCs which progress rapidly and a 
shorter screening interval might be beneficial [111].  This is currently being tested in Phase 2 
of the UKFOCSS, which is a prospective single arm screening study involving 5700 women 
[209]. Screening is based on four monthly CA125 testing, interpreted using the ROC 
algorithm and an annual TVS. The trial will report in 2013. Reports of screening in this 
population are also anticipated in 2013 from the US trials, the GOG-199 study and the US 
Cancer Genetics Network trial [112]. In the absence of a validated screening programme, 
women in the UK NHS who are at increased risk of familial ovarian cancer are counselled for 
genetic testing and offered the option of undergoing risk reducing surgery once they have 
completed their family.  
Other early detection strategies 
For decades ovarian cancer has been considered a disease with minimal symptoms until 
advanced stage. In 2000, a large retrospective survey conducted by Goff and  colleagues 
[113] showed that up to 95% of women experienced symptoms between 3-6 months prior to 
diagnosis The most common symptoms were abdominal (77%), gastrointestinal (70%), pain 
(58%), constitutional [(0%), urinary (34%), and pelvic (26%) with gynaecologic symptoms 
being the least common. Interestingly, symptoms were not related to stage and even in 
women who were diagnosed with early stage disease, 89% reported symptoms. The 
frequency and severity of the symptoms was reported to be higher in women with ovarian 
cancer than in women with other conditions [114,115].  However, in many such studies the 
positive predictive value was low and retrospective data was used for analysis. Nonetheless, 
it was generally agreed that awareness of OC symptoms in women and primary care 
physicians may help to reduce the time to specialist referral and/or investigation. To this end 
consensus statements were issued by the Gynecologic Cancer Foundation, the Society of 
Gynecologic Oncologists, and the American Cancer Society in the US and also in the UK, a 
consensus statement and information leaflets were released by cancer charities and 
Department of Health listing the most frequently observed symptoms associated with ovarian 
cancer [81, 82, 212,213]. In the UK The National Institute for Health and Clinical Excellence 
[NICE] recently recommended that a CA125 test should be offered to women with symptoms 
suggestive of ovarian cancer, with aim of obtaining an earlier diagnosis [214]. Women with 
higher levels of the marker would then be offered an ultrasound scan while those with 
persistent symptoms but normal levels would be offered repeat testing.  There has been 
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concern from the medical community that these guidelines were not based on prospective 
studies and the implications of wide spread CA125 testing had not been assessed [116,117]. 
A symptom index developed by Goff and colleagues [118] has been recently tested in 
combination with CA125 and HE4 in a prospective case – control study involving 74 women 
with OC and 137 healthy women controls.  The SI alone had sensitivity of 64% with 
specificity of 88%. A rule based on any two of the three tests being positive had a sensitivity 
of 84% with a specificity of 98.5% [119], with a positive rate of 1.5%. The authors suggest 
that the use of such an instrument as a first line test, may be helpful in selecting women for 
further diagnostic testing [118]. Further independent testing of this approach is warranted. 
Data relating to symptoms in women enrolled into UKCTOCS are been collected 
prospectively. This is currently being analysed [Menon, personal communication]. 
More recently, results from a prospective pilot study using a symptoms based approach has 
been published. Women aged 50yrs and over who presented with symptoms of ovarian 
cancer were offered CA125 testing and TVS [120].  In 1455 women assessed, 22 
gynaecological cancers were diagnosed, 11 were invasive epithelial ovarian cancer, nine of 
which were high grade serous carcinoma. Five were associated with only slightly raised 
CA125 concentrations and minimal or no ovarian abnormalities on TVS.  73% tumours were 
completely resectable in study patients, compared to 44% in clinic patients. Though these 
observations are promising, a larger ideally randomised controlled trial is needed to confirm 
these data and ensure that the findings are not due to a ‘healthy volunteer effect’ [121]. 
Shifting sands  
There is no evidence at present that screening for ovarian cancer has a mortality benefit and 
the latest USPSTF recommendation reflects this [122]. OC screening instead may cause 
harm. However, mortality data from two randomised trials, SCSOCS and UKCTOCS are still 
awaited and these will provide valuable information for future recommendations.  In parallel, 
recent mathematical modelling studies have suggested that current methodologies might be 
incapable of detecting ovarian cancers at an earlier stage or at most have a modest effect on 
mortality rates [123, 124]. Unpublished data from our group suggests that in some cases the 
ROC may facilitate detection of small volume disease [Menon 2012].  
Also emerging at this time, is increasing evidence that the origins of ovarian cancers may not 
be rooted in ovary itself but in other tissues [125]. Most high grade serous EOCs in BRCA1/2 
mutation carriers and also in about 50-60% of women with sporadic ovarian cancers are 
thought to initiate in the fimbriae of the fallopian tube [126-128]. With ultrasound scanning 
focussed only on the ovarian tissue, it is understandable why earlier high grade serous 
cancers may be missed.. New technologies such as autofluorescence for detection of these 
cancers are now being investigated by a Canadian group [129]. 
There is increasing recognition that ovarian cancer is not one disease but several 
multifaceted entities. Five main histological subtypes of ovarian cancer [serous, mucinous, 
clear cell, endometrioid and transitional cell/Brenner tumors] have been identified, which 
differ with respect to genetic mutations, precursor lesions, stage of presentation and 
responsiveness to chemotherapy [130-132]. A recent proposed model for categorising these 
different cancers into two main types, (Type I and Type II), has recently been proposed by 
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Kurman and Shih [133, 134] based on tumour behaviour and pathogenic pathways.  Type I 
cancers include low-grade serous carcinoma, low-grade endometrioid carcinoma, mucinous 
carcinoma, Brenners tumours and a subset of clear cell carcinomas. These cancers are 
genetically stable and rarely express TP53.They are slow growing, have defined precursor 
lesions and are generally detected at an early stage. Type II tumours on the other hand are 
genetically unstable, have high level of TP53 mutations and are aggressive, rapidly growing 
carcinomas which are detected at an advanced stage. The high mortality rates in ovarian 
cancer arise mainly from these latter type of cancers, which make up 75% of all epithelial 
ovarian cancers. Type II cancers include the high-grade serous, high-grade endometrioid, 
malignant mixed mesodermal tumours and undifferentiated carcinomas. High grade serous 
ovarian cancers make up the large proportion of type II cancers. Although the dualistic 
model is a good one, there are concerns that it does not cater for differences between the 
histotypes in Type I group. Given the recent insights into disease aetiology and 
heterogeneity of OC, there is increasing need for novel detection methods that are histotype-
specific. There are concerns that current strategies such as ultrasound scanning and serum 
CA125  may be biased towards detection of Type I and Type II  tumours respectively.  
A very recent publication by Kinde et al [2013] [135] has ignited much interest. These 
authors described the use of a sensitive massively parallel sequencing method for detecting 
gynaecological cancer associated somatic mutations in LBC samples from 24 endometrial 
cancers and 22 ovarian cancers. Their technique detected 100% of endometrial cancers and 
41% of ovarian cancers offering the possibility that a single test [LBC] could be used for 
detecting the presence of multiple gynaecological cancers. However, this requires further 
confirmation, validation and research before use in clinical practice. 
 
Uterine cancer 
Like ovarian cancer, uterine cancer is more common in the industrialised nations than in the 
developing world [215]. It is the leading gynaecological cancer in North America (ASR 16.4 
per 100,000), Europe (ASR 12.3), Australia/New Zealand (ASR 11.5). The lowest rates are 
observed in Africa (ASR 2.6 per 100,000).  In the UK 7,468 women were diagnosed with 
uterine cancers in 2008 and 1,554 died of the disease. 93% of uterine cancer cases are 
diagnosed in women aged 50 years and over. Incidence rates peak in the early seventies at 
83 per 100,000 and begins to decline from 75 years onwards [215]. The majority of uterine 
cancers are endometrial with less than 4% being uterine sarcomas. This review will focus on 
endometrial cancer.   
Endometrial cancer is becoming a concern as its incidence has risen in recent years. In 
America which has the highest incidence of this cancer, a 21% increase has been observed 
since 2008 and the mortality from the condition has increased by 8% during the same time 
[136]. In the UK the incidence of endometrial cancer has risen by nearly 20% [216] in the last 
decade and mortality rates have increased from 3.1 to 3.7 per 100,000 since the late 1990s 
[216]. A recent assessment of data from an English cancer registry showed that the greatest 
increases have been observed in the 60-79 years age group [137]. The increase in 
endometrial cancer is thought to be related to the rise in obesity, women having fewer 
children and the aging population [138].  
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Other risk factors include unopposed oestrogen stimulation, late menopause, diabetes 
mellitus, nulliparity, feminising ovarian tumours, polycystic ovarian syndrome, use of 
tamoxifen and familial disposition. The key driver appears to be unopposed oestrogen, which 
after menopause arises from aromatisation of androstenedione to oestrone in the adipose 
tissue. The risk for endometrial cancer is higher in obese women [139, 140], with this being 
reported as six times higher in women with a BMI ≥ 40 compared lean women  in one report 
[139]. The risk of death in women with endometrial cancer who have a BMI ≥ 40 is also 
increased [RR 6.25] [136,140].   
Two types of endometrial cancers have been described [141]. Type I (80%) cancers occur in 
younger, obese, or perimenopausal women and are associated with oestrogen. They are 
usually low-grade, histologically characterised as endometroid and have a good prognosis. 
They arise from hyperplastic changes with a definable precursor lesion, atypical endometrial 
hyperplasia [AEH]. The thickened endometrium is detectable by ultrasound.  Ten percent of 
endometrial cancers are Type II cancers, which occur in older women and express neither 
estrogen nor progesterone receptors. Type II cancers are high grade malignancies, with a 
serous or clear cell histology, which resemble aggressive serous or clear cell cancers seen 
in the ovary or cervix. Prior radiotherapy may be a risk factor for development of these 
cancers [136]. Type II cancers appear as focal thickening in a thin endometrium and can be 
missed on ultrasonography. In the US these types of cancers are more frequently seen in 
African-American women and have a poor outcome [136, 142].  Data from a West Midlands 
cancer registry showed that [137] that whilst survival rates remain stable for Type I, 5 year 
rates in Type II cancers have fallen significantly from 55.1% to 40.9% [(P<0.001). 
A family history should be ascertained in all endometrial cancer cases as 10% are hereditary 
[136]. Such cancers arise as part of the Lynch syndrome [LS], also known as hereditary 
nonpolyposis colorectal cancer [HPNCC] [143,144].  Both Type I or Type II cancers are 
represented in LS. Families are identified based on the Amsterdam II [145] or on the revised 
Bethseda Criteria [146]. LS is an autosomal dominant syndrome caused by germline 
mutations in any one of the DNA mismatch repair [MMR] genes: mutL homolog 1 (MLH1), 
mutS homolog 2 (MSH2), postmeiotic segregation increased 1 (PMS1), post-meiotic 
segregation increased 2 (PMS2) and mutS homolog 6 (MSH6) [136]. Proteins encoded by 
the MMR genes are critical to the repair of DNA sequence mismatch. Loss of MMR function 
leads to DNA replication errors in the simple short-tandem DNA repeat sequences of 1 to 6 
bases, called microsatellites. As a result these microsatellites lengthen or shorten, a process 
known as microsatellite instability [136,144]. Women who have these mutations are at risk of 
developing colorectal, ovarian and endometrial cancer. More recently there is evidence that 
the range of cancers that can occur in these families is greater than originally believed 
[147,148].  The lifetime risk of endometrial cancer is estimated to be between 30-70% and 
dependent on the type of mutation [149]. Other studies suggest a lower risk of 14%–30% 
when controlled for ascertainment bias [150]. Using the genotype restricted likelihood (GRL) 
method accounting for this bias, a recent French study reported cumulative risks for 
endometrial cancer as 54% (95% CI, 20%-80%), 21% (95% CI, 8%-77%), and 16% (95% CI, 
8%-32%) for MLH1, MSH2 and MSH6 respectively by 70yrs of age [151]. By age 40 years 
the estimated cumulative risks did not exceed 2% (95% CI, 0%-7%) for this cancer for the 
genes tested, suggesting that prophylactic surgery in these women could be considered 
after this age. 
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Screening for Endometrial Cancer 
Screening is not advocated for endometrial cancer in the low risk population as 95% of the 
women become symptomatic whilst the cancer is still at an early stage and curable. The 
commonest presentation is abnormal vaginal bleeding and approximately 10% of women 
with postmenopausal bleeding [PMB] are diagnosed with endometrial cancer. 72% of these 
cancers are stage I, 12%are stage II, 13% are stage III, and 3% are stage IV [136].  
The overall five year survival is 77% [217]. As result only a few studies [138, 152-156] have 
assessed the benefits of screening in this population. However, as the population grows not 
only in number but also in girth and lives longer, the question arises whether women at risk 
of developing endometrial cancer could be identified and lesions detected earlier. The 
presence of a precursor lesion, AEH, also raises the possibility of impacting on incidence as 
in cervical cancer. A nested case-control study of endometrial cancer and AEH was 
undertaken using data from 37,038 women who underwent TVS in the ultrasound arm of 
UKCTOCS [138]. An endometrial thickness (ET) of 10mm, had a sensitivity of 54·1% (95% 
CI45·3–62·8) and would lead to approximately 17 diagnostic interventions per case 
detected. A lower ET threshold of >5mm would increase sensitivity (80·5% (95% CI72·7–
86·8)) but result in 56 diagnostic procedures per case. A logistic regression model was 
developed incorporating epidemiological data [of the use of the oral contraceptive pill, age at 
menarche, number of pregnancies, weight, age, and history of cancer] to stratify women 
according to risk of endometrial cancer. Based on the data available for women who 
represented the top 25% of an ‘at high risk’ population, cut-off of an endometrial thickness of 
6.75mm achieved sensitivity of 84·3% (95% CI71·4–93·0) and specificity of 89·9% (95% 
CI89·3–90·5) for endometrial cancer. 39·5% of known endometrial cancer or AEH cases 
were located with this top quartile of women.  An approach such as this may help to triage 
women with a complement of risk factors for future screening investigations. 
At present regular medical surveillance is restricted to those women who are at risk of LS, 
and wish to delay or avoid preventative surgery. Endometrial cancer in LS women is often 
diagnosed in their forties and fifties, some 10-20 years earlier that in low risk women. 
Screening is recommended from the age of 35 using TVS and endometrial sampling (with or 
without hysteroscopy) [176/156,177/157].An endometrial thickness of 3-5mm on TVS 
triggers further investigation.  
Pipelle endometrial biopsy is a well-established method for endometrial sampling that can be 
performed as an outpatient procedure. However, it has a tissue yield and procedure failure 
rate of around 10% [178/158] and inadequate samples are more common in the post-
menopausal age group. Cancers have been reported to be missed on pipelle alone. A large 
meta-analysis reported a 99% sensitivity of pipelle to diagnose endometrial cancer and 81% 
for hyperplasia in postmenopausal women and a sensitivity of 91% in premenopausal 
women, while maintaining a specificity of >98%.[178/158]  
Hysteroscopy directed endometrial sampling is the accepted gold-standard and is now 
routinely performed as an outpatient procedure. No significant difference in pain scores has 
been reported between approaches using either hysteroscopy or endometrial sampling 
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alone [159]. In addition, initial reports did not find any psychological morbidity associated 
with hysteroscopy-based endometrial screening in LS [160]. Hysteroscopy can detect 
pathology which may be missed by both ultrasound and pipelle [161,162]. Hysteroscopy has 
been found to detect premalignant lesions in two asymptomatic cases in one surveillance 
study [161]. No screen detected cancers were reported in asymptomatic high-risk women 
undergoing annual hysteroscopy in two earlier reported series [154, 163] Out-patient 
hysteroscopy failure rates of 8% and 11% were found in these two series.  
Results of a more recent prospective observational cohort study of 41 LS women attending a 
tertiary high-risk familial gynaecological cancer clinic have been reported [164]. These data 
show that showed annual outpatient hysteroscopy and endometrial sampling (OHES) is 
acceptable to the women and has high diagnostic accuracy for endometrial cancer. 4 cases 
of endometrial cancer/ atypical endometrial hyperplasia were detected using this approach 
compared to two detected by TVS. OHES had similar specificity of 89.8 % (CI 79.2, 96.2 %), 
but higher positive likelihood ratio (PLR) 9.8 (CI 4.6, 21) and lower negative likelihood ratio   
(NLR) (0) compared to TVS: specificity 84.75 % (CI 73, 92.8 %), PLR 3.28 (CI 1.04, 10.35) 
and NLR 0.59 (CI 0.22,1.58). The results of the study reinforce the current recommendation 
that endometrial sampling is crucial when screening these women but suggest the need for 
larger studies. 
 
Expert Commentary 
This is an exciting time in gynaecological oncology with our understanding of disease 
pathogenesis increasing in leaps and bounds. This is set to shape the future landscape for 
screening in female cancers. In cervical cancer it is likely that HPV testing will replace 
cytology as the primary tool for screening in both high and low income settings. In addition 
tests specific for assessing malignant potential of precancerous lesions, for example E6 and 
E7 oncoproteins expression, will help tailor management protocols. HPV vaccination 
programs have been implemented in  a number of countries  and impact on cervical cancer 
screening programmes will only be known in the next decade or so.  
In ovarian cancer, the most lethal of all gynaecological malignancies, there continues to be 
no evidence that screening can save lives. Mortality data from the largest randomised 
controlled trial [UKCTOCS] will be available in 2015. Meanwhile advances in molecular and 
genetic profiling has revealed the extent of epithelial OC heterogeneity, highlighting the need 
to refine screening strategies to take into account detection of the individual histological 
types. Most intriguing of all is the increasing evidence for the non- ovarian origins of OC, 
especially of high grade serous malignancies which exhibit an aggressive, fast progressing 
phenotype. 
Endometrial cancer is increasing at an alarming rate and thought to be linked in part to the 
obesity epidemic. Serious consideration should be given to limit this increase. Improved risk 
stratification strategies in the general population with targeted screening within a defined 
higher risk sub-group may further improve screening performance.  
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Five year view  
The gynaecology oncology community is on the cusp of changes which will alter 
management of common gynaecological cancers. The approach to screening in the general 
population will be more focussed with improved risk stratification at its core. Driving this will 
be the rapid growth in technology and access to biobanked samples that predate cancer 
diagnosis that will help unveil additional molecular and genetic pathways of these cancers.  
Secondly, as the world population grows, and places additional burden on healthcare 
resources, there is need to target  those at greatest risk.  
The incidence of cervical cancer will change as the global pool of vaccinated women 
enlarges and more women have access to screening. Primary HPV testing with cytology 
triage is the most likely future strategy for cervical cancer screening over the next five years. 
Molecular testing will continue to focus on genotypes HPV 16, 18 and HPV45 and 
associated markers of malignant transformation.  Low cost assays are already being tested 
in developing countries where the disease burden is the greatest. Structured screening 
programmes will be implemented in many countries which do not as yet have one. The high 
negative predicator value of the HPV testing means that longer screening intervals are 
feasible and in low resource countries even one or two rounds of screening will significantly 
lower the risk of cervical cancer.  The key to reduction will require policy makers and 
healthcare providers to ensure that coverage is maximal, there is quality assurance of the 
screening programmes and appropriate treatment facilities.   
The future of ovarian cancer screening in the UK will be decided once the two largest 
prospective screening trials, UKFOCSS in high–risk women and UKCTOCS in low-risk 
women, report in 2013 and 2015 respectively. The trial designs in these studies differ from 
the earlier trials that have already reported negative results and the outcomes are awaited 
beyond the UK. Meantime, there will be a significant growth in studies trying to unravel the 
heterogeneity of ovarian cancer so that more finely tuned early detection modalities may be 
adopted. There is a significant effort underway already to identify humoral or tissue based 
biomarkers of preclinical disease and to develop newer assays for their detection. Predictive 
modelling using genetic and epidemiological and clinical data to define risk will assist in this 
triage.  
The increase in endometrial cancer is alarming. The control of this cancer is in part related to 
the wider efforts in the management of the obesity pandemic. A high level UN meeting in 
2011 has already called for action in tackling the negative impact of unhealthy lifestyles on 
the incidences of cancers and other non-communicable diseases such as CVD and 
diabetes. Raising awareness of the risk factors of this disease is warranted. Models for 
identifying women at increased risk of developing sporadic cancer are being developed and 
will help identify a higher risk group who could benefit from screening for this disease. 
Prospective trials which evaluate mortality and quality of life outcomes will be needed to 
validate this approach.  
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Key issues 
Gynaecological cancers are a significant cause of morbidity and mortality in women 
worldwide.  
Cervical cancer 
• Cervical cancer is preventable as the causative agent HR-HPV is known and 
precancerous lesions are well characterised and detectable on screening 
• A wide variety of screening tests to suit varying needs have been developed and 
evaluated. The latest tests undergoing evaluation include HPV E6/E7 mRNA and 
cheaper, rapid throughput fields test such as careHPV. 
• Primary HPV testing has emerged as the most likely future strategy  
• A mortality benefit has been shown in large randomised controlled trials following 
even a single round of screening 
• In low to middle income countries where the bulk of the disease is observed, the 
urgent need is to implement cervical screening programmes using cost effective 
strategies such as visual inspection and to introduce quality assurance where such 
programmes already exist. 
• In developing countries, where such programmes have been a success, the need is 
improve coverage especially in younger women and to fine tune screening strategies 
to identify women most at risk whilst minimising overdiagnosis and over treatment. 
Recent guidelines will assist in this effort. 
• Vaccination programmes have begun alongside screening in over 100 countries 
Ovarian cancer 
• The most lethal of al gynaecological cancers. More than 60% of women with ovarian 
cancer will die within 5 years of diagnosis. 
• Utility of screening uncertain at present. One large randomised controlled  trial has 
reported no mortality benefit while results of the second larger trial with a different 
screening strategy are awaited 
• Increasing understanding of the heterogeneity and natural history of ovarian cancer 
will allow development of novel screening approaches.  
• The future focus needs to be to develop assays and optimise strategies for detection 
of low volume primary invasive epithelial ovarian cancer 
Endometrial cancer   
• Rates of endometrial cancer are escalating. Approximately 50% are related to 
obesity, which is also on the rise. Other factors are decreasing parity and age. 
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• Screening not available currently because women are usually symptomatic and 
diagnosed in early stages when prognosis is good.  
• Currently available strategy using TVS has high false positive rates and needs further 
optimising 
• There is need to develop risk stratification methods to identify women in the general 
population at increased risk  
• Screening strategy for high risk Lynch Syndrome women needs to be optimised 
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